Edition:
United States

Lombard Medical Inc (EVAR.OQ)

EVAR.OQ on NASDAQ Stock Exchange Capital Market

0.55USD
27 Jun 2017
Change (% chg)

$0.01 (+1.85%)
Prev Close
$0.54
Open
$0.56
Day's High
$0.56
Day's Low
$0.54
Volume
3,592
Avg. Vol
26,935
52-wk High
$1.45
52-wk Low
$0.40

Latest Key Developments (Source: Significant Developments)

Lombard Medical names Kurt Lemvigh CEO
Thursday, 20 Apr 2017 02:25pm EDT 

April 20 (Reuters) - Lombard Medical Inc ::Lombard Medical appoints new CEO.Kurt Lemvigh has been appointed as its new Chief Executive Officer, effective immediately.  Full Article

Lombard Medical Q4 global revenue $2.4 million, FY 2016 revenue $12.2 mln
Tuesday, 18 Apr 2017 03:34am EDT 

April 18 (Reuters) - Lombard Medical Inc :For Q4, global revenue was $2.4 million and $12.2 million for full year 2016.Qtrly loss per ordinary share from continuing operations $0.37.  Full Article

Lombard Medical CEO Simon Hubbert steps down
Tuesday, 18 Apr 2017 03:33am EDT 

April 18 (Reuters) - Lombard Medical Inc ::Lombard Medical's CEO steps down.Simon Hubbert has stepped down from his position as CEO on April 18.A search is underway for a successor and an announcement is expected in due course.  Full Article

Lombard Medical Q3 loss per share $0.37
Thursday, 27 Oct 2016 04:00pm EDT 

Lombard Medical Inc : Lombard Medical reports 2016 third quarter, nine-month financial results . Q3 loss per share $0.37 . Q3 revenue $3.0 million versus $4.2 million .Lombard Medical - Partially offsetting reduction in revenue in quarter was performance in European direct markets.  Full Article

Lombard Medical reports Q2 loss per share $0.42
Monday, 22 Aug 2016 04:00pm EDT 

Lombard Medical Inc : Reports 2016 second quarter, six-month financial results and provides update on strategic initiatives . Q2 loss per share $0.42 . Q2 revenue $3.8 million versus I/B/E/S view $3.8 million . Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S . Board of directors has engaged Cain Brothers as its investment banker to begin a process of exploring strategic alternatives . Exploring strategic alternatives, including a potential sale of company or disposition of certain assets . Company will also be evaluating additional financing opportunities . Allocating resources to support new Altura AAA stent graft system and Intelliflex LP delivery system for Aorfix in European Union, Japan and other international markets . Due to suspension of US commercial operation, says "prudent" to amend revenue guidance for year to between $13 million and $15 million .Aorfix sales force in us has been eliminated and majority of commercial operations have transitioned to company's facility in UK.  Full Article

Lombard Medical launches altura endovascular stent graft system in Netherlands and Spain
Wednesday, 6 Jul 2016 06:00am EDT 

Lombard Medical Inc :Expanded European launch of its new altura endovascular stent graft system to Netherlands and Spain.  Full Article

Lombard Medical wins Australia approval for aneurysm device
Monday, 6 Jun 2016 06:00am EDT 

Lombard Medical Inc :Received australian tga approval for aorfix endovascular stent graft for treatment of abdominal aortic aneurysms.  Full Article

Lombard Medical Inc Q1 loss per share $0.38
Wednesday, 11 May 2016 04:00pm EDT 

Lombard Medical Inc : Expects to achieve year-over-year revenue growth in 2016 of approximately 20 percent . FDA approval and corresponding us launch of Intelliflex remains on track for late 2016 or early 2017 . Lombard Medical reports 2016 first quarter financial results . Q1 revenue $2.9 million versus $3.4 million . Q1 revenue view $3.6 million -- Thomson Reuters I/B/E/S . Q1 loss per share $0.38 .Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Lombard Medical Inc lowers FY 2015 revenue guidance
Wednesday, 4 Nov 2015 04:00pm EST 

Lombard Medical Inc:Revised its outlook and now expects revenue for FY 2015 of between $15 - 16 million.FY 2015 revenue of $18 million - Thomson Reuters I/B/E/S.  Full Article

Lombard Medical acquires endovascular stent graft developer Altura Medical
Thursday, 30 Jul 2015 07:01am EDT 

Lombard Medical Inc:Says terms of the transaction include the issuance of $15 million of Lombard common stock at $4 per share.Says up to $27.5 million may be paid based on the achievement of certain commercial and regulatory milestones.Terms include assumption of $5.5 million in bank debt and $2.5 million in certain liabilities and transaction-related costs.Says under the terms of the agreement, Lombard has the option to pay the additional consideration in either cash or stock.  Full Article

More From Around the Web

BRIEF-Lombard Medical names Kurt Lemvigh CEO

* Kurt Lemvigh has been appointed as its new Chief Executive Officer, effective immediately Source text for Eikon: Further company coverage:

No consensus analysis data available.